A retrospective study assessing the tolerability and efficacy of CBD-rich cannabis in children with ASD.
PUBLISHED CLINICAL RESEARCH
Over the last decade, our skilled team of scientists and nurses at Tikun Olam Israel have treated more than 20,000 patients, conducting laboratory research and clinical trials on medical cannabis therapy and the effectiveness of our strains. Below is an outline of our published studies and ongoing research.
View our Medical Research Bookautism,
Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems
Journal of Autism and Developmental Disorders, 2023
Key Results:
fibromyalgia,
Safety and Efficacy of Medical Cannabis in Fibromyalgia
Publisher: Journal of Clinical Medicine, 2023
This observational study investigated the characteristics, safety, and effectiveness of medical cannabis therapy for fibromyalgia. Patients studied were referred to cannabis after receiving traditional treatment for at least a year without improvement. The change in symptoms and quality of life was measured after six months of treatment.
Key Results:
autism,
Real Life Experience of Medical Cannabis with Autism: Analysis of Safety and Efficacy
Scientific Reports, 2023
This observational study assessed the safety and efficacy of medical cannabis for the treatment of autism spectrum disorders (ASD), analyzing the change in symptoms after six months of using our CBD-rich cannabis oil.
Key Results:
Tourette's syndrome,
Single Center Experience with Medical Cannabis in Gilles De La Tourette Syndrome
Parkinsonism and Related Disorders, 2023
This study was conducted to assess the response and benefits of using cannabis to treat Tourette Syndrome.
Key Results:
multiple sclerosis,
Avidekel Cannabis Extracts and Cannabidiol are as Efficient as Copaxone in Suppressing EAE in SJS/J Mice
Inflammopharmacology, 2023
This study compared the efficacy of purified CBD, extracts of CBD-rich Avidekel, and Copaxone (glatiramer acetate), an immunosuppressive medication that is used to alleviate the symptoms of multiple sclerosis (MS).
Key Results:
complex motor disorders,
Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders
Journal of Child Neurology, 2023
A clinical random trial examining the effects of Avidekel oil on dystonia and spasticity in children who suffer from cerebral palsy or genetic impairment. Most participants reported significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and quality of life.
Key Results:
palliative cancer care,
Prospective Analysis of Safety and Efficacy of Medical Cannabis in Large Unselected Population of Patients with Cancer
European Journal of Internal Medicine, 2023
This study analyzed the data routinely collected as part of the treatment program of cancer patients treated with medical cannabis between 2015 and 2017. The most frequent types of cancer were breast (20.7%), lung (13.6%), pancreatic (8.1%) and colorectal (7.9%), and 51.2% of patients were at Stage 4. The main symptoms requiring therapy were sleep problems (78.4%), pain (77.7%; median intensity 8/10), weakness (72.7%), nausea (64.6%) and lack of appetite (48.9%). The study concluded that cannabis is a well-tolerated, effective and safe option to help patients cope with cancer-related symptoms.
Key Results:
palliative geriatric care,
Epidemiological Characteristics, Safety and Efficacy of Medical Cannabis in the Elderly
European Journal of Internal Medicine, 2023
A prospective study that analyzed the use of cannabis treatment in the elderly, measuring for pain intensity, quality of life, and adverse effects at six months follow-up. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%). The study found that the therapeutic use of cannabis is safe and efficacious in the elderly population.
Key Results:
parkinson's disease,
Medical Cannabis in Parkinson’s Disease
Clinical Neuropharmacology, 2023
A retrospective questionnaire-based survey that examined the effects of cannabis on the motor and non-motor symptoms of patients with Parkinson’s Disease. The mean age of the patients was 64.2 +/- 10.8 years, the mean disease duration was 10.8 +/- 8.3 years, and the duration of cannabis use was 19.1 +/- 17 months.
Key Results:
pain & inflammation,
Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
Pharmacology & Pharmacy, 2023
This laboratory study was conducted on rodents to examine the effect of full-plant cannabis extract on inflammation and pain, in comparison with isolated CBD and commercial anti-inflammatory and anti-nociceptive drugs. Isolated CBD has been shown to have a bell-shaped dose-response, where healing is only observed within a very limited dose range, with no additional beneficial effect achieved at lower or higher doses. This trait of purified CBD poses challenges to clinical use; thus, this study aimed to find a CBD source that eliminates the bell-shaped dose response – and succeeded with Avidekel.
Key Results:
Crohn's disease,
Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: A Randomized Placebo-Controlled, Double-Blind Study
Clinical Gastroenterology & Hepatology, 2023
In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 45% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.
Key Results:
Crohn's disease,
Treatment of Crohn’s Disease with Cannabis: An Observational Study
The Israel Medical Association Journal, 2023
This retrospective study observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).
Key Results:
CLINICAL STUDIES IN PROGRESS
IBD,
Cannabis and IBD Data Collection
Large-scale long-term data collection study on patients using medical cannabis that suffer from inflammatory bowel disease (IBD), to determine the effect of cannabis use on the symptoms and adverse side effects of the disease.
colitis,
The Effects of Cannabis on Colitis
Clinical research comparing a group of Colitis patients who will be given Erez strain cannabis and a group who will be given placebo for a period of eight weeks, during which the effect of cannabis on blood inflammation indices, life quality, medicine consumption, and adverse side effects, etc., will be monitored.
Crohn's disease,
The Effects of Cannabis on Crohn’s Disease
Clinical research comparing a test group, receiving the Avidekel strain, and a control group (placebo), to examine the effect of cannabis oil administered as treatment for inflammatory intestinal disease.
LABORATORY RESEARCH IN PROGRESS
immunology,
The Effects of Cannabis on Immune Response
A study analyzing the effect of extracts of Avidekel, Erez and Midnight on immune response in blood samples in which infection was induced. Preliminary results show a verification of a suppressing effect of natural cannabinoids on the release of inflammation triggering cytokines; indication of a possible inflammation preventing effect of CBD on the immune system.